Regal Assets Analytics

SanaCurrents on Insmed’s (INSM) entry in pulmonary arterial hypertension (PAH)

By |2022-05-18T13:37:33-04:00May 7th, 2022|Tags: |

Insmed, Inc. (NASDAQ:INSM) Probability Sentiment SUMMARY Pulmonary arterial hypertension (PAH) comprises a group of severe [...]

SanaCurrents Pivotal on Humacyte’s (HUMA) regenerative blood vessels

By |2022-05-03T12:23:54-04:00April 30th, 2022|Tags: |

Humacyte, Inc. (NASDAQ:HUMA) Probability Sentiment SUMMARY Regenerative medicine, the therapeutic research devoted to the regrowth [...]

SanaCurrents on Relmada’s (RLMD) push for REL-1017 to treat depression

By |2022-04-04T08:18:31-04:00April 2nd, 2022|Tags: |

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Probability Sentiment SUMMARY While current anti-depressants provide some relief, most physicians [...]

SanaCurrents on Albireo’s (ALBO) approved drug Bylvay to treat Alagille syndrome

By |2022-04-04T08:16:38-04:00March 27th, 2022|Tags: |

Albireo Pharma, Inc. (NASDAQ:ALBO) Probability Sentiment SUMMARY Alagille syndrome (ALGS) is a rare, life-threatening genetic [...]

SanaCurrents on Apellis’ (APLS) clinical rebound to treat rare form of blindness

By |2022-04-04T08:17:02-04:00March 19th, 2022|Tags: |

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Probability Sentiment SUMMARY Apellis Pharmaceuticals is advancing a portfolio of drugs [...]

SanaCurrents Pivotal Sentiment on new Glaukos (GKOS) procedure for rare eye disease

By |2022-03-06T21:04:20-05:00March 6th, 2022|Tags: |

Glaukos subsequently advanced a second-generation treatment, Epioxa, through phase III trials. SanaCurrents assigns a pivolat probability Glaukos will submit an NDA for Epioxa in 2022.

Go to Top